← back to search

Martin Schmidt‐Hieber

Charité - Universitätsmedizin Berlin · DE
Area of research
Hematology · Oncology
Research interest
Research interests include Medicine, Internal medicine, Lenalidomide, Multiple myeloma, Intensive care medicine, and Dexamethasone.
h-index
citations
797
works
24
NIH funding
primary concept
email

Recent publications

2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies
The Lancet Regional Health - Europe 2025cited by 24position: middledoi
CNS infections in patients with hematological or oncological diseases (including cellular therapies) – 2024 update of the guideline of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
European Journal of Cancer 2025cited by 2position: lastdoi
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Journal of Clinical Oncology 2024cited by 55position: middledoi
Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma
Blood 2024cited by 1position: middledoi
Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
Journal of Antimicrobial Chemotherapy 2023cited by 87position: middledoi
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study
Transfusion Medicine and Hemotherapy 2023cited by 8position: middledoi
A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma
European Journal of Cancer 2023cited by 6position: middledoi
Impact of the insertion site of central venous catheters on central venous catheter-related bloodstream infections in patients with cancer: results from a large prospective registry
Infection 2023cited by 6position: middledoi
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation
Transfusion Medicine and Hemotherapy 2023cited by 6position: middledoi
Chlorhexidine gluconate‐coated gel pad dressings for prevention of central venous catheter‐related bloodstream infections in patients with hematologic diseases or autologous stem cell transplantation: A registry‐based matched‐pair analysis
European Journal Of Haematology 2023cited by 3position: middledoi
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
Haematologica 2022cited by 6position: middledoi
Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
Blood 2022cited by 4position: middledoi
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
Blood 2021cited by 0position: middledoi
Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Mycoses 2020cited by 72position: middledoi
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Leukemia 2020cited by 67position: middledoi
Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation
Expert Review of Anti-infective Therapy 2019cited by 55position: firstdoi
Central venous catheter–related bloodstream infections in patients with hematological malignancies: Comparison of data from a clinical registry and a randomized controlled trial
Infection Control and Hospital Epidemiology 2019cited by 12position: middledoi
Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE
Clinical Lymphoma Myeloma & Leukemia 2019cited by 0position: middledoi
Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse
Blood 2018cited by 14position: middledoi
Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma
Blood 2018cited by 13position: middledoi
Cyclophosphamide‐based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase <scp>III</scp> trial Re<scp>LA</scp>psE
European Journal Of Haematology 2017cited by 20position: middledoi
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
BMC Cancer 2016cited by 7position: middledoi
Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology
Annals of Oncology 2014cited by 104position: middledoi
CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT
Blood 2013cited by 225position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

· 7 papers (2014–2025)Daniel Teschner · Johannes Gutenberg University Mainz7 papers (2019–2025)Jens Panse · Stem Cell Institute5 papers (2019–2025)Marcus Hentrich · BMW (Germany)5 papers (2014–2023)Markus Ruhnke · Helios Vogtland Klinikum Plauen4 papers (2014–2025)Georg Maschmeyer · Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie4 papers (2014–2023)Maximilian Christopeit · Universität Hamburg3 papers (2014–2025)Boris Böll · Medical University of Vienna3 papers (2019–2023)Hans Salwender · Asklepios Klinik Altona3 papers (2014–2018)Olaf Penack · European Society for Blood and Marrow Transplantation3 papers (2014–2023)Oliver A. Cornely · Agostino Gemelli University Polyclinic3 papers (2020–2025)Meinolf Karthaus · München Klinik3 papers (2014–2023) · 2 papers (2017–2018) · 2 papers (2017–2018) · 2 papers (2020–2023)Timo Schmitt · Johannes Gutenberg University Mainz2 papers (2023–2023)Katja Weisel · National Institute Of Blood Disease and Bone Marrow Transplantation2 papers (2017–2018)Jan‐Hendrik Naendrup · University of Pittsburgh Medical Center2 papers (2023–2023)Jannik Stemler · Centrum für Integrierte Onkologie2 papers (2023–2025)Stefan Schwartz · Humboldt-Universität zu Berlin2 papers (2020–2025)